← All trials
NCT04529538
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2021
- Primary completion
- Apr 30, 2022
- Completion date
- Aug 31, 2022
- First posted
- Aug 27, 2020
- Last posted
- Nov 30, 2020
- Enrollment
- 230
- Arms / groups
- 8 / —
- Source
- AACT · ingestion pipeline
Sponsors
- PATHLead sponsor
- Dartmouth UniversityOverall official - principal investigator
- University of North Carolina at Chapel HillOverall official - principal investigator
- Centers for Disease Control and Prevention (CDC)Collaborator
- University of VermontOverall official - principal investigator
- Bill and Melinda Gates FoundationCollaborator
- The EMMES CorporationCollaborator
- Viroclinics Biosciences B.V.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.